PATENT CLAIM ANALYSIS

Application Number: 15894350
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "489000"]

Abstract:
The invention relates to methods and compositions for treating demyelination and/or dysmyelination and/or promoting remyelination of neurons and/or preventing the development of myelin-related diseases by administering to a subject in need thereof an effective amount (either therapeutic or prophylactic) of an elemental gold crystal nanosuspension.

Claim (Index 6):
Use according to  claim 1 , wherein said composition is taken orally.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 1.14286
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14005690', '14374703', '12965771', '12513197', '12799670']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7695180684567261
- 35 USC 102 Novelty (BERT): 0.5310817144668981
- Combined Prediction Score: 0.7456744330577433
- Mean Citation Score: 292.9381400000001
- Max Citation Score: 303.39905
- Similarity Product: 145.67981596312822

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test